The following stood out as focus areas among early-stage players in the field:
Despite their early success, cell therapies still require significant work to improve their safety and reach. Improving the immunogenic profiles of therapies and reducing the burden of complex manufacturing and long treatment timelines will require innovation. This area attracted more than $3 billion in VC funding in 2022. The following stood out as focus areas among early-stage players in the field: